Sinogene
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sinogene - overview
Established
2012
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Established in 2012 and based in Beijing, China, Sinogene operates as a biotechnology company that focuses on pet cloning and gene editing. In 2021, the company has completed five rounds of financing. The company provides services of cat cloning, dog cloning, horse cloning, and cell preservation. The gene preservation (GP) consists in storing the pet genetic material so that it can be used even after decades.
The Genetic preservation is accomplished by freezing the initial cell, tissue or germ plasma in the liquid nitrogen with low temperature.
Current Investors
Lotus Lake Capital, Shuncheng Equity Investment Fund, CCB International Asset Management
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.sinogene.com.cn
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.